Understanding Genetic Testing
the poma difference
We make sure that carrier screening occurs in the same laboratory for both partners because the genetics laboratories will then provide PGT-M testing for a nominal fee.
Many clinics recommend PGT biopsy and freezing all the embryos to allow a frozen embryo transfer of a euploid (normal) embryo. We offer this policy as well, but we also offer transfer of a fresh untested embryo is not any riskier than a natural or IUI conception and prevents having to wait for a frozen embryo transfer with the necessary delay and potential cost increase of a frozen cycle.
We use a laboratory, Genomic Predictions Laboratory, that uses technology to minimize the diagnosis of mosaic embryos, which can create challenges regarding the decision of which embryo to transfer.
Carrier screening refers to a blood test to determine if the sperm and egg both contain a single gene mutation, called autosomal recessive. When the sperm and the egg both carry the same autosomal recessive gene mutation, the resulting child has a 25% chance of disease. Carrier screening allows usto identify carriers and use PGT technology to diagnose disease in embryos which then permits us to transfer only unaffected or carrier embryos andprevent disease transmission.
Preimplantation Genetic Testing (PGT) is a technique for removing a few cells from an embryo to allow testing for genetic abnormalities. PGT comes in 3 forms: PGT-A (aneuploidy) evaluates the number of chromosomes and an embryo; PGT-M (mutation) evaluates the embryo for an autosoma lrecessive disease (predicted by carrier screening); and PGT-SR (structural rearrangement) evaluates chromosomes that have structural changes such as a translocation. PGT-A is the most common technique used to identify embryos that have the normal number of chromosomes and provide the highest probability of a successful implantation and pregnancy.
To learn more about working with POMA Fertility, please schedule your consultation today, or give us a call at 425.822.7662